secwatch / observer
8-K filed December 26, 2023, 6:59 PM ET ticker TNON CIK 0001560293
other material confidence high sentiment negative materiality 0.60

Tenon Medical stockholders approve reverse split, adjourn meeting for charter amendment vote

Tenon Medical, Inc.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 1.0

Tenon Medical, Inc. shareholders approved To consider and vote on a proposal to approve, for purposes of Nasdaq Listing Rule 5635(d) and Nasdaq Listing Rule 5635(b), the issuance of the maximum number of shares of our common stock issuable under the terms of Series A Preferred Stock and Warrants to be issued by the Company to investors at the 2023-12-21 meeting.

Outcome
passed
Meeting
2023-12-21
Exact text from the filing
Proposal No. 1 – To consider and vote on a proposal to approve, for purposes of Nasdaq Listing Rule 5635(d) and Nasdaq Listing Rule 5635(b), the issuance of the maximum number of shares of our common stock issuable under the terms of Series A Preferred Stock and Warrants to be issued by the Company to investors; For Against Abstain 938,808 35,310 11,668
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 1.0

Tenon Medical, Inc. shareholders rejected To consider and vote on a proposal to approve an amendment (the "Blank Check Preferred Amendment") to the Company's Second Amended and Restated Certificate of Incorporation, as amended (the "Certificate of Incorporation"), to expressly vest in the Board of Directors of the Company (the "Board") the at the 2023-12-21 meeting.

Proposal
charter amendment
Outcome
failed
Meeting
2023-12-21
Exact text from the filing
Proposal No. 2 – To consider and vote on a proposal to approve an amendment (the "Blank Check Preferred Amendment") to the Company's Second Amended and Restated Certificate of Incorporation, as amended (the "Certificate of Incorporation"), to expressly vest in the Board of Directors of the Company (the "Board") the authority to issue the preferred stock with powers, designations, preferences and relative, participating, optional or other rights, if any, or the qualifications, limitations or restrictions thereof as the Board; For Against Abstain 903,573 65,526 16,687
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 1.0

Tenon Medical, Inc. shareholders approved To consider and vote on the proposal to adjourn the Special Meeting, if necessary or appropriate, to solicit additional proxies. at the 2023-12-21 meeting.

Outcome
passed
Meeting
2023-12-21
Exact text from the filing
Proposal No. 4 – To consider and vote on the proposal to adjourn the Special Meeting, if necessary or appropriate, to solicit additional proxies. For Against Abstain 1,356,229 127,140 10,132
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 1.0

Tenon Medical, Inc. shareholders approved To consider and vote on a proposal to approve an amendment (the "Reverse Stock Split Amendment") to the Certificate of Incorporation to provide for a reverse stock split (the "Reverse Stock Split") of the Common Stock, that will be at a ratio ranging from one for two (1:2) to one for fifty (1:50) (t at the 2023-12-21 meeting.

Proposal
reverse split
Outcome
passed
Meeting
2023-12-21
Exact text from the filing
Proposal No. 3 – To consider and vote on a proposal to approve an amendment (the "Reverse Stock Split Amendment") to the Certificate of Incorporation to provide for a reverse stock split (the "Reverse Stock Split") of the Common Stock, that will be at a ratio ranging from one for two (1:2) to one for fifty (1:50) (the "Split Ratio Range"), the final determination of which shall be determined by the Board; and For Against Abstain 1,378,827 114,415 5,261
View on SEC.gov

63 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Tenon Medical, Inc. filing history →

Source: SEC EDGAR
accession 0001213900-23-098519
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.